Welcome to our dedicated page for CapsoVision SEC filings (Ticker: CV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions. These regulatory documents offer detailed insight into the company’s financial condition, risk factors, governance, and product development activities.
CapsoVision’s filings include periodic reports that present net revenue from sales of its CapsoCam Plus capsule endoscopy system, costs of revenue, operating expenses for selling and marketing, research and development, and general and administrative functions, as well as information on cash and cash equivalents and stockholders’ equity. Current Reports on Form 8-K disclose material events such as quarterly financial results, executive appointments or departures, and key regulatory submissions, including applications to the FDA for 510(k) clearance and Breakthrough Device Designation.
On Stock Titan, each new filing from EDGAR is surfaced in near real time and paired with AI-powered summaries that explain the key points in clear language. Instead of reading entire multi-page documents, users can review concise highlights of items such as results of operations, changes in leadership, or updates on clinical and regulatory programs for products like CapsoCam Plus, CapsoCam Colon, and CapsoCam UGI.
Investors can also use this page to locate disclosures related to equity structure, the company’s initial public offering, and compensation or appointment details for senior executives, as reported in 8-K filings. By combining direct access to original SEC documents with AI-generated explanations, this section helps users understand how CapsoVision’s regulatory and financial reporting reflects the evolution of its AI-enabled capsule endoscopy business.
Tsai Chen Lung reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc. director Tsai Chen Lung reported receiving a grant of 4,045 Restricted Stock Units on March 19, 2026. Each RSU represents a contingent right to receive one share of CapsoVision common stock, giving him rights to 4,045 underlying shares after this award.
The RSUs vest in two equal installments, with 50% scheduled to vest on June 30, 2026 and the remaining 50% on December 31, 2026, subject to his continued service on the board through each vesting date. Following this grant, he holds 4,045 RSUs directly.
Kuo Hui Ying reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc. reported that director Kuo Hui Ying received a grant of 4,045 Restricted Stock Units (RSUs), each representing one share of common stock. This is a compensation-related award rather than an open-market trade, and it brings the director’s reported holdings to 4,045 RSUs.
The RSUs vest in two equal parts: 50% on June 30, 2026 and 50% on December 31, 2026, conditioned on continued service on the board through each vesting date. No cash price was paid for the award.
King Wen-Herng Henry reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc director King Wen-Herng Henry reported receiving a grant of 4,045 Restricted Stock Units (RSUs) tied to the company’s common stock. Each RSU represents a contingent right to receive one share of common stock if vesting conditions are met.
The award is scheduled to vest in two equal tranches, with 50% vesting on June 30, 2026 and the remaining 50% vesting on December 31, 2026, subject to his continued service on the board through each vesting date. Following this grant, his reported direct holdings consist of 4,045 RSUs.
Imperial Joanne Carol reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc director Joanne Carol Imperial received a grant of 4,045 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of CapsoVision common stock.
The award vests in two equal installments: 50% on June 30, 2026 and 50% on December 31, 2026, subject to her continued service as a non-employee director through each vesting date. Following this grant, she holds 4,045 RSUs directly, and this filing reflects a compensation-related award rather than an open-market share purchase or sale.
Harari Michele reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc. reported that director Michele Harari received a grant of 4,045 restricted stock units (RSUs), each representing the right to receive one share of common stock. The award is a form of equity compensation rather than an open-market purchase.
The RSUs are scheduled to vest in two equal installments, with 50% vesting on June 30, 2026 and the remaining 50% on December 31, 2026, subject to Harari’s continued service on the board through each vesting date. Following this grant, Harari holds 4,045 RSUs directly.
GOUW JULIA S reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc. reported that director Julia S. Gouw received a grant of 4,045 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of CapsoVision common stock, so the grant covers 4,045 potential shares.
The RSUs vest in two equal tranches, with 50% scheduled to vest on June 30, 2026 and the remaining 50% on December 31, 2026. Vesting is conditioned on her continued service as a non-employee director on the board through each vesting date.
CapsoVision, Inc. entered into a securities purchase agreement with accredited investors for a $14 million private placement, issuing 2,867,089 common shares at $4.883 per share, a 5% discount to the March 16 closing price. The company plans to use the cash for sales and marketing, R&D, general corporate purposes and working capital.
CapsoVision reported preliminary, unaudited revenue of $3.9 million for the fourth quarter of 2025 and $13.6 million for full year 2025, with approximately $10.1 million in cash, cash equivalents, restricted cash and investments as of December 31, 2025.
The company decided not to pursue FDA clearance for its first-generation CapsoCam Colon capsule after 510(k) feedback, and is prioritizing a second-generation version supported by an expanded pivotal study targeting about 800 patients, with over 500 enrolled and a planned 510(k) submission in the third quarter of 2026. CapsoVision is also developing a pancreatic cancer screening application using its CapsoCam UGI system; an initial Breakthrough Device Designation request was not approved, and the company expects to resubmit after a planned study of about 90 patients starting in the second quarter of 2026.
CapsoVision, Inc. amended its development agreement with Canon Inc. for CMOS image sensors, increasing the total fee by $1 million to reflect enhanced specifications. This raises the original approximately $4.1 million commitment, increasing the remaining development fee that will be paid through sensor purchase pricing. The amendment keeps the defined Additional Amount unchanged and confirms that all other terms, including the structure for future sensor purchases and clinical and FDA 510(k) objectives, remain in full force and effect.
CapsoVision, Inc director Tsai Chen Lung reported an open-market purchase of common stock. A joint brokerage account for Tsai and his wife bought 20 shares of CapsoVision common stock at $4.17 per share on July 3, 2025. This Form 4/A is an amendment, filed because the transaction was inadvertently omitted from the original Form 4 submitted on July 7, 2025. After this trade, the account held 20 shares directly.
CapsoVision, Inc. reported higher Q3 results but remained unprofitable. Net revenue for the three months ended September 30, 2025 was $3.538 million versus $2.966 million a year ago, with gross profit of $1.914 million. Operating expenses rose to $9.933 million, driving a quarterly net loss of $7.921 million and a nine‑month net loss of $17.921 million. Cash and cash equivalents were $17.787 million as of September 30, 2025.
The company completed an IPO in July 2025, raising approximately $23.37 million in net proceeds and converting all preferred stock into common shares after a 1‑for‑3.33 reverse split. Management disclosed that current conditions “raise substantial doubt” about the ability to continue as a going concern. CapsoVision also entered a $4.1 million development agreement with Canon for CMOS sensors, paying $1.0 million at effectiveness and carrying an outstanding purchase commitment of $2.5 million. Revenue was driven mainly by U.S. product sales, while service revenue included cloud delivery and physician reading services.